

KRAS; A KEY ONCOGENIC DRIVER AND NOVEL INVESTIGATIONAL TARGET IN NSCLC



Join us for a session on KRAS. The program will feature expert speakers reviewing the evolving NSCLC landscape and emerging biomarkers, raise awareness that KRAS G12C is the most prevalent emerging molecular target in NSCLC, define patient and tumor characteristics, and discuss clinical guideline recommendations for molecular testing at diagnosis of NSCLC.

FLASCO Members Participate for **FREE!**



Meghan Borysova, PhD

Senior Medical Science Liaison, Amgen

Meghan Borysova is a Tampa based Oncology Medical Science Liaison at Amgen, based in Thousand Oaks, California. Her role focuses on solid tumors, covering approved products as well as pipeline molecules. Meghan has a PhD in Cancer Biology from Moffitt Cancer Center and the University of South Florida. Meghan's doctoral research focused on the molecular mechanisms of carcinogenesis, specifically, on mitosis and genomic instability as a driver of tumorigenesis. During her postdoctoral training she worked on elucidating the etiologies of cancer health disparities.

SPEAKERS



Amanda Struckhoff, PhD

Medical Science Liaison, Amgen

Amanda Struckhoff is a native Floridian having grown up in St. Augustine Florida. She received her B.S. in Chemistry from Kennesaw State University and earned her Ph.D. in Pharmacology from Tulane University. She has over 15 years of experience in translational and clinical cancer research with publications in neurooncology, viruses in cancer, and mechanisms of cancer metastasis. She is currently an Oncology Medical Science Liaison with Amgen. She enjoys spending time with 2 children, and, non-COVID times, traveling and enjoying the music and food culture in her hometown of New Orleans, LA.



DATE: Thursday, October 1, 2020

TIME: 12:15 PM – 1:15 PM

LOCATION: Virtual Program

RSVP: [REGISTER](#)

DATE: Thursday, October 8, 2020

TIME: 6:00 PM – 7:00 PM

LOCATION: Virtual Program

RSVP: [REGISTER](#)

Support provided by:



AMGEN